Nashville R&D Tax Credit Explained for Businesses

R&D Tax Credits for Nashville, Tennessee Businesses

Nashville, Tennessee, is a major hub for industries such as healthcare, music, education, finance, and technology. Top companies in the city include HCA Healthcare, a leading healthcare provider; Sony Music Entertainment, a major music employer; Vanderbilt University, a significant educational institution; Dollar General, a key player in the finance sector; and Asurion, a prominent technology company. The Research and Development (R&D) Tax Credit can help these industries save on taxes by encouraging innovation and technological advancements.

Are you eligible?

Why choose us?

Pass an Audit?

Swanson Reed is one of the only companies in the United States to exclusively focus on R&D tax credit preparation. Swanson Reed’s office location at 1910 Madison Avenue, Memphis, Tennessee is less than 210 miles away from Nashville and provides R&D tax credit consulting and advisory services to Nashville and the surrounding areas such as: Clarksville, Murfreesboro, Franklin, Hendersonville and Smyrna.

If you have any questions or need further assistance, please call or email our local Tennessee Partner on (901) 254-7002.
Feel free to book a quick teleconference with one of our Tennessee R&D tax credit specialists at a time that is convenient for you. Click here for more information about R&D tax credit management and implementation.

Schedule a Teleconference

Nashville, Tennessee Patent of the Year – 2024/2025

Pendant Biosciences Inc. has been awarded the 2024/2025 Patent of the Year for its innovation in controlled drug delivery. Their invention, detailed in U.S. Patent No. 11905377, titled ‘Factors controlling drug release in cross-linked poly(valerolactone) based matrices’, introduces a customizable polymer platform designed to enhance the precision and efficiency of therapeutic drug release.

Traditional drug delivery systems often struggle with inconsistent release rates and limited adaptability to different drugs. Pendant Biosciences addresses this challenge by developing a cross-linked polymer matrix that allows for tunable control over drug release profiles.

The technology utilizes a copolymer composed of poly(valerolactone), poly(allylvalerolactone), and polyethylene glycol. By adjusting the composition and cross-linking density of this matrix, the release rate of encapsulated drugs can be finely controlled. This adaptability ensures that a wide range of therapeutic agents can be delivered effectively, maintaining optimal concentrations over desired timeframes.

Such precision in drug delivery is particularly beneficial for chronic conditions requiring sustained medication levels, potentially improving patient compliance and treatment outcomes. Moreover, the biodegradable nature of the polymer matrix minimizes long-term residue in the body, enhancing safety profiles.

Pendant Biosciences’ advancement represents a significant step forward in personalized medicine, offering a versatile solution that can be tailored to meet specific therapeutic needs across various medical fields.